Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OBIO vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

OBIO Overall Winner 6-Pillar Tally: OBIO 4 – 1 PLUR (1 Tie) Matrix Metrics: OBIO 6 – 4 PLUR

As of Nov 17, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $7.02 (N/M Forward P/E, -195.4% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. PLUR 28.8/100 SELL) and 1.15β · 80% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs PLUR
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 80% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 68
RSI-14: 68.1 · SMA20: $5.99 · SMA50: $5.94
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (OBIO 4 – 1 PLUR)

Columns: Metric · OBIO · PLUR
1. Valuation Multiples PLUR
Forward P/E N/M 3.6x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue 18.6x 44.6x
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% -15.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $1.0M
Market Cap $570.6M $15.1M
3. Profitability & Quality OBIO
Gross Margin 99.6% 44.6%
Operating Margin -195.4% -2454.5%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -1022.0%
4. Balance Sheet & Cash Flow OBIO
Cash Generation (TTM) -$64M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 70.8% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (6) vs PLUR (4)
Institutional Metric OBIO PLUR Criterion Row Edge
Market Capitalization
Scale
$570.6M $15.1M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-89.4% -15.8% Higher Growth PLUR
Operating Margin (TTM)
Profitability
-195.4% -2454.5% Higher Margin OBIO
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin PLUR
Return on Equity (ROE)
Capital Efficiency
-182.3% -1022.0% Higher ROE OBIO
52-Week Range Position
Momentum
89% ($3–$7) 2% ($1–$5) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.15β · 80% Vol 0.80β · 102% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
$31M $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +13.16 pp
OBIO: +24.25% · PLUR: +11.09%
3M Horizon OBIO +72.83 pp
OBIO: +26.49% · PLUR: -46.34%
6M Horizon OBIO +138.02 pp
OBIO: +75.5% · PLUR: -62.52%
1Y Horizon OBIO +153.7 pp
OBIO: +78.17% · PLUR: -75.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue PLUR Revenue OBIO Op. Margin PLUR Op. Margin Margin Leader
FY2018 N/A $0M N/A -67462.0% PLUR
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 N/A $0M N/A -128156.5% PLUR
FY2022 $0M $0M -924.3% -17774.8% OBIO
FY2023 $0M $0M -1866.2% -9493.4% OBIO
FY2024 $0M $0M -2437.5% -6796.9% OBIO
FY2025 $30M $0M -154.7% -1659.9% OBIO
FY2026 N/A $0M N/A -2454.5% PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $7.02 (N/M Forward P/E, -195.4% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. PLUR 28.8/100 SELL) and 1.15β · 80% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), OBIO cumulative revenue shifted N/A while PLUR shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

PLUR screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.